Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
10-Year Return on Invested Incremental Capital (10-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 10-year.
Anti-Microbialvior BioteQ Co does not have enough data to calculate 10-Year ROIIC %.
Anti-Microbialvior BioteQ Co (ROCO:6864) 10-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Anti-Microbialvior BioteQ Co 10-Year ROIIC % Related Terms
Anti-Microbialvior BioteQ Co 10-Year ROIIC % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Anti-Microbialvior BioteQ Co 10-Year ROIIC % Chart
ROCO:6864 vs VRTX, REGN, RVMD: 10-Year ROIIC % Comparison
For the Biotechnology subindustry, Anti-Microbialvior BioteQ Co's 10-Year ROIIC %, along with its competitors' market caps and 10-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Anti-Microbialvior BioteQ Co 10-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Anti-Microbialvior BioteQ Co's 10-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Anti-Microbialvior BioteQ Co's 10-Year ROIIC % falls into.
10-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
10-Year Incremental Invested Capital**
=
( -95.985 (Dec. 2025) - (Dec. 2015) )
/
( 47.776 (Dec. 2025) - (Dec. 2015) )
=
/
=
N/A%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 10-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Anti-Microbialvior BioteQ Co (ROCO:6864) has a 10-Year ROIIC % of -426.87 as of Dec. 2025. 10-Year ROIIC % measures the change in earnings as a percentage of change in investment over 10-year. View historical data on Anti-Microbialvior BioteQ Co and its competitors. According to the industry distribution chart, Anti-Microbialvior BioteQ Co ranks #941 out of 1101 companies in the Biotechnology industry, placing it in the top 85.5%.
Is Anti-Microbialvior BioteQ Co's 10-Year ROIIC % too high?
Anti-Microbialvior BioteQ Co's current 10-Year ROIIC % is -426.87. Based on the distribution chart, Anti-Microbialvior BioteQ Co ranks #941 out of 1101 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Anti-Microbialvior BioteQ Co has a GF Score™ of 60/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Anti-Microbialvior BioteQ Co's 10-Year ROIIC % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Anti-Microbialvior BioteQ Co ranks #941 out of 1101 companies for 10-Year ROIIC %. This places Anti-Microbialvior BioteQ Co in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 10-Year ROIIC % for a Biotechnology company?
A good 10-Year ROIIC % depends on the Biotechnology industry context. However, 10-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 10-Year ROIIC % mean?
A high 10-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 10-Year ROIIC % measures the change in earnings as a percentage of change in investment over 10-year. View historical data on Anti-Microbialvior BioteQ Co and its competitors. Anti-Microbialvior BioteQ Co's current 10-Year ROIIC % is -426.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anti-Microbialvior BioteQ Co stock overvalued right now?
Based on GuruFocus' analysis, Anti-Microbialvior BioteQ Co (ROCO:6864) is currently considered Significantly Overvalued. The stock's GF Value™ is NT$25.08, compared to a current price of NT$41.85 — trading 66.9% above its estimated fair value. The current 10-Year ROIIC % is -426.87. Anti-Microbialvior BioteQ Co's overall GF Score™ is 60/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 10-Year ROIIC % calculated?
10-Year ROIIC % is calculated from a company's financial statements. For Anti-Microbialvior BioteQ Co (ROCO:6864), the current 10-Year ROIIC % is -426.87 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Anti-Microbialvior BioteQ Co (ROCO:6864) Overvalued in 2026?
Based on GuruFocus' analysis, Anti-Microbialvior BioteQ Co stock appears to be overvalued.
The current stock price of NT$41.85 is trading 66.9% above its estimated GF Value™ of NT$25.08.
GuruFocus considers Anti-Microbialvior BioteQ Co to be Significantly Overvalued.
Key valuation signals for ROCO:6864:
10-Year ROIIC %: -426.87
GF Value™: NT$25.08 vs. price of NT$41.85 (66.9% above fair value)
No single metric tells the full story. See the ROCO:6864 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6864 has been successfully added to your 
